|
Welichem Biotech is pleased to announce that the clinical component of a Phase IIa trial on Atopic Dermatitis (a form of eczema) has been completed
BURNABY, BC, CANADA | June 19, 2008 | Welichem Biotech Inc. (the "Company") (TSX- V: WBI), a biotechnology company developing therapeutic drugs for the treatment of anti-inflammatory and auto-immune diseases and cancer, is pleased to announce that the clinical component of a Phase IIa trial on Atopic Dermatitis (a form of eczema) has been completed. The final report on this randomized, double-blinded, vehicle-controlled study to evaluate the safety, tolerability and efficacy of topically applied WBI-1001 cream in subjects with Atopic Dermatitis (AD) is expected later this summer.
Atopic Dermatitis is a chronic, inflammatory condition that causes the skin to become inflamed, cracked and itchy. It occurs worldwide, its prevalence is increasing and in North America it affects over 15 million people. The condition is especially prevalent in young children. Current therapeutic treatments have variable efficacy and often undesirable side effects.
The Company has initiated plans for a Phase IIb clinical trial to further evaluate the properties of WBI-1001 as a topical cream application against AD.
SOURCE: Welichem Biotech Inc.
|
